medicine: tamibarotene

tamibarotene description








Tamibarotene, also called retinobenzoic acid, is orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity.

Further reading

"Tamibarotene: AM 80, retinobenzoic acid, Tamibaro". Drugs in R&D (6): 359-62. 2004. PMID 15563242. 
This medical article is a stub. You can help Wikipedia by expanding it.v • d • eRetrieved from "http:en.boinc.org/boinc/Tamibarotene"Categories: Medicine stubs | Retinoids | Antineoplastic drugs

Tags

Keywords related to tamibarotene

travatan octriptyline amrinone fortamet azepindole cefonicid cinanserin ipodate sodium etonogestrel pharmacia 26 upjohn company iofendylate homidium bromide bromhexine inversine rescula terizidone oxymetholone mofezolac ethisterone lurosetron meticorten cyclophosphamide piperidolate difetarsone accure thioacetazone thenyldiamine amcinonide anhydron eribulin halflytely milrinone etazolate fareston romazicon aerosporin dextropropoxyphene ribasphere simvastatin tolonium chloride minaxolone mandol definity rimantadine tris alimemazine hydroflumethiazide leucocyanidin actron trileptal citicoline norvir cyamemazine nydrazid vospire avandia


  • Related news


    CytRx Corporation Completes Acquisition of Innovive Pharmaceuticals,
    "In the short-term, we expect tamibarotene and our pipeline of drugs in The efficacy of orally-administered tamibarotene was demonstrated in two Phase 2 ...
    Read full article

    CytRx Announces Publication of Paper Stating that Chaperone
    The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a potential registration ...
    Read full article

    CytRx's Tamibarotene Receives Positive Opinion from the Committee for
    CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, ...
    Read full article

    CareFirst and WellDoc Communications Sponsor Diabetes Clinical Trial
    Article: Clinical Trial Combining Tamibarotene with Trisenox Wireless News; September 18, 2009 ; 700+ words Wireless News 09-18-2009 Clinical Trial ...
    Read full article

    CytRx Unveils Clinical Development Plan for Pipeline Assets
    We believe tamibarotene has strong potential as a revenue generator with a Our view is based on the substantial clinical history of tamibarotene as an ...
    Read full article

    CytRx Secures Key European Patent for Arimoclomol
    The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a registration study for the ...
    Read full article

    CytRx to Present at the OneMedForum 2010 Conference
    The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a registration clinical ...
    Read full article

    CytRx leukemia drug gets positive opinion from EMEA
    O) said a panel of the European Medicines Agency (EMEA) has recommended an orphan drug status for tamibarotene, its experimental bone marrow cancer ...
    Read full article

    Company Profile Report
    Bafetinib/INNO-406 (Tyrosine Kinase Inhibitor); Tamibarotene (Synthetic Retinoid); INNO-206 (Doxorubicin Prodrug); INNO-305 (Cancer Vaccine) ...
    Read full article

    Press Release: SunPower Corporation (NASDAQ:SPWRA) is the Highest
    Today (July 24, 2009), CytRx Corporation announced that its drug candidate tamibarotene has received official notification from the Committee for Orphan ...
    Read full article

    Clinical Trial Combining Tamibarotene with Trisenox to Begin
    Clinical Trial Combining Tamibarotene with Trisenox to Begin find Wireless News articles. Wireless News 09-18-2009 Clinical Trial Combining Tamibarotene ...
    Read full article

    Ardea Biosciences Begins Phase 2b Clinical Trial of RDEA594 Article
    Article: Clinical Trial Combining Tamibarotene with Trisenox Wireless News; September 18, 2009 ; 700+ words Wireless News 09-18-2009 Clinical Trial ...
    Read full article

    CytRx Announces $20 Million Registered Direct Offering
    With the completion of this financing, we are positioned to aggressively pursue our goals of moving tamibarotene and INNO-206 toward commercialization, ...
    Read full article

    CytRx Reports Progress Update for Its Pivotal Phase 2 Clinical Trial
    CytRx holds the North American and European rights to tamibarotene, a rationally In addition, CytRx expects tamibarotene to be granted European orphan ...
    Read full article

    CytRx Corporation Signs Definitive Agreement to Acquire Innovive
    Tamibarotene is presently in a pivotal Phase 2 clinical trial in APL, and CytRx anticipates In April 2005, tamibarotene was approved in Japan for use in ...
    Read full article

    Announces Positive Phase 2 Results For Tamibarotene in the
    CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company, today announced favorable preliminary results from its Phase 2 STAR-1 registration clinical ...
    Read full article

    CytRx to Discuss Recent Progress at the Lippert/Heilshorn & Associates
    The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a clinical trial for the ...
    Read full article

    Press Release: QualityStocks News - CytRx Corp. (CYTR) Awarded
    CytRx Corp. announced that tamibarotene received an official positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European ...
    Read full article

    CytRx rises on analyst's 'Outperform' rating
    Until then, he said a leukemia drug candidate called tamibarotene could aid CytRx's CytRx is currently conducting midstage tests of tamibarotene. ...
    Read full article

    Proteolix to Present Carfilzomib Clinical Data at the 2009 ASCO
    Wireless News; July 3, 2009 ; 700+ words of tamibarotene in other fields Tamibarotene significant anti-tumor activity in an animal trial for ...
    Read full article

    CytRx Expands Management Team and Broadens Oncology Franchise
    The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a clinical trial for the ...
    Read full article

    Press Release: "Stocks that Standout" picks for today are: CYTR,
    The primary endpoint of the open-label, non-randomized STAR-1 trial is to determine the rate of durable complete response for tamibarotene therapy when ...
    Read full article

    MMRC Multiple Myeloma Genomics Initiative Sequences Complete
    Wireless News; July 3, 2009 ; 700+ words of tamibarotene in other fields Tamibarotene significant anti-tumor activity in an animal trial for ...
    Read full article

    Frost & Sullivan: E-clinical Trial Solutions Markets Show Potential
    Article: Clinical Trial Combining Tamibarotene with Trisenox Wireless News; September 18, 2009 ; 700+ words Wireless News 09-18-2009 Clinical Trial ...
    Read full article

    Cytrx Corp (CYTR.W) Company Profile Stocks Reuters.com
    Tamibarotene is a synthetic retinoid designed to overcome resistance and avoid toxic side Tamibarotene was developed to overcome resistance to ATRA. ...
    Read full article

    New 52 Week High Breakout Alerts Baidu, Inc. (NasdaqGS: BIDU)
    CytRx Corporation (CYTR) aid a panel of the European Medicines Agency (EMEA) has recommended an orphan drug status for tamibarotene, its experimental bone ...
    Read full article

    CytRx Fortifies Executive Suite with Addition of Chief Medical Officer
    "I am looking forward to using my skills to advance the development of several potentially important oncology drug candidates, such as tamibarotene as a ...
    Read full article

    CytRx to Acquire Innovive Pharmaceuticals
    Tamibarotene is presently in a pivotal Phase II clinical trial in APL, and CytRx anticipates that the acquisition will accelerate the time to its first ...
    Read full article

    Prominent Oncologist David R. Parkinson, MD, Joins CytRx's Clinical
    The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a registration study for the ...
    Read full article

    Medegenics Introduces Preliminary Data for Clinical Trial Article
    Article: Clinical Trial Combining Tamibarotene with Trisenox Wireless News; September 18, 2009 ; 700+ words Wireless News 09-18-2009 Clinical Trial ...
    Read full article

    Article: pSivida Plans Clinical Trial to Assess Safety and Efficacy
    Article: Clinical Trial Combining Tamibarotene with Trisenox Wireless News; September 18, 2009 ; 700+ words Wireless News 09-18-2009 Clinical Trial ...
    Read full article

    INNO-406 Demonstrates Positive Clinical Responses in Phase 1
    The CytRx drug development pipeline includes six programs in clinical development, including tamibarotene in registration studies for the treatment of acute ...
    Read full article

    CytRx closes on Innovive Los Angeles Business from bizjournals
    The biggest name amongst the drugs is tamibarotene, a treatment for leukemia. The drug has already been approved in Japan, and is currently being studied in ...
    Read full article

    Update for Its Pivotal Phase 2 Clinical Trial with Tamibarotene as
    CytRx holds the North American and European rights to tamibarotene, a rationally In addition, CytRx expects tamibarotene to be granted European orphan ...
    Read full article

    CytRx Corporation Announces Second Quarter Results
    Steven Kriegsman continued, "The drug candidate tamibarotene is a key asset in Based on successful development of tamibarotene, a New Drug Application ...
    Read full article

    StreetInsider.com - CytRx (CYTR) and Cephalon (CEPH) Oncology
    CytRx Corporation (NASDAQ: CYTR) announced the initiation of a dose escalation study with its oncology drug candidate tamibarotene combined with TRISENOX ...
    Read full article

    CytRx and Cephalon Oncology Therapies to be Evaluated as Treatment
    We hypothesize that the combination of tamibarotene and arsenic While currently focused on US approval for tamibarotene, CytRx considers Orphan Drug ...
    Read full article

    Memgen to Present Results of ISF35 Clinical Trial at ASCO Annual 2009
    Article: Clinical Trial Combining Tamibarotene with Trisenox Wireless News; September 18, 2009 ; 700+ words Wireless News 09-18-2009 Clinical Trial ...
    Read full article

    CytRx Announces That FDA Lifts Clinical Hold of Arimoclomol in ALS
    The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a registration study for the ...
    Read full article

    Update For Its Pivotal Phase 2 Trial With Tamibarotene As A Third
    CytRx holds the North American and European rights to tamibarotene, a rationally In addition, CytRx expects tamibarotene to be granted European orphan ...
    Read full article

    CytRx shares fall on delay for Lou Gehrig's drug
    Innovive's latest stage candidate is tamibarotene, in midstage development for a kind of acute myeloid leukemia, the most common type of leukemia. ...
    Read full article

    CytRx Reports 2009 Third Quarter Financial Results
    In September, a dose escalating trial with tamibarotene in combination with arsenic trioxide injection was initiated to determine an appropriate dose for ...
    Read full article

    Press Release: CytRx Corporation (NASDAQ:CYTR) Xtreme picks of the
    Today's news alerts include: CytRx's Tamibarotene Demonstrates Statistically Significant Anti-Tumor Activity in Animal Trial for Multiple Myeloma ...
    Read full article

    CytRx Announces 2009 Clinical and Development Milestones
    Tamibarotene: The Company plans in the second and fourth quarters to report While currently focused on US approval for tamibarotene, CytRx considers ...
    Read full article

    Medidata Solutions Launches Clinical Trial Technology Partners
    Article: Clinical Trial Combining Tamibarotene with Trisenox Wireless News; September 18, 2009 ; 700+ words Wireless News 09-18-2009 Clinical Trial ...
    Read full article

    CytRx reports positive study data on tamibarotene in animal trial for
    CytRx reports positive study data on tamibarotene in animal trial for multiple myeloma. M2 EUROPHARMA-(C)1999-2009 M2 COMMUNICATIONS ...
    Read full article

    CytRx's Tamibarotene Demonstrates Statistically Significant Anti
    LOS ANGELES - (Business Wire) CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company engaged in the development of high-value ...
    Read full article

    CytRx Announces Plan to Initiate a Phase 2 Clinical Trial with INNO
    The CytRx drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a clinical trial for the ...
    Read full article